Search results

Found 1,514 pages
AUTHOR: Anna Smith

Results per page

10 20 50 100

Sort by

Relevance Date

30 May 2019:

Univar’s Cufence leads latest CHMP decisions

The committee recommended four treatments including two generic medicines. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/univars_cufenceleads_latest_chmp_decisions_1289447

4 Jan 2019:

NHS winter figures encouraging ahead of ‘toughest days’

The NHS Confederation has said that the latest NHS winter figures are encouraging, but that the ‘toughest days may well come later’. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/nhs_winter_figures_encouraging_ahead_of_toughest_days_1273777

14 Nov 2019:

NICE ‘OK’ for Sativex in MS

The organisation updates its MS Guideline to state that Sativex should be offered to treat spasticity in people with the disorder. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/nice_ok_for_sativex_in_ms_1317024

31 Jan 2020:

LEO issues Picato recall

Last September, the EMA's Pharmacovigilance Risk Assessment Committee announced a review of data on skin cancer in patients using the drug. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/leo_issues_picato_recall_1323880

10 Apr 2019:

Novartis’ Kisqali hit with NICE rejection

The drug is typically used with fulvestrant to treat people with advanced breast cancer. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/novartis_kisqali_hit_with_nice_rejection_1284180

4 Sep 2019:

NICE nod for Novartis’ Luxturna

The treatment has been approved for RPE65-mediated inherited retinal dystrophies. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/nice_nod_for_novartis_luxturna_1300705

25 Feb 2019:

Santhera’s Syros succesful in DMD study

Santhera Pharmaceuticals has announced results from its Syros DMD study. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/santheras_syros_succesful_in_dmd_study_1279276

2 Apr 2019:

Circassia’s COPD drug gets FDA approval

The approval is based on data from three Phase III studies, ACLIFORM, AUGMENT and AMPLIFY. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/circassias_copd_drug_gets_fda_approval_1283092

25 Mar 2019:

FDA rejects oral Type I diabetes drug

The FDA has dashed Sanofi's hopes of launching its type I diabetes drug, Zynquista, this year. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/fda_rejects_oral_type_i_diabetes_drug_1282499

20 Dec 2018:

Lynparza gets FDA approval for ovarian cancer

Lynparza has been approved in the US for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer. - News - PharmaTimes

by Anna Smith

https://www.pharmatimes.com/news/lynparza_gets_fda_approval_for_ovarian_cancer_1273230